196 related articles for article (PubMed ID: 32748236)
1. Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis.
Gatti M; Poluzzi E; De Ponti F; Raschi E
Drug Saf; 2020 Dec; 43(12):1277-1285. PubMed ID: 32748236
[TBL] [Abstract][Full Text] [Related]
2. Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements.
Indraccolo U; Conzadori S; Greco P
Recenti Prog Med; 2019 Feb; 110(2):98-99. PubMed ID: 30843536
[TBL] [Abstract][Full Text] [Related]
3. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program.
Donnez J; Arriagada P; Marciniak M; Larrey D
Expert Opin Drug Saf; 2018 Dec; 17(12):1225-1232. PubMed ID: 30460871
[TBL] [Abstract][Full Text] [Related]
4. An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
Kang S; Brinker A; Jones SC; Dimick-Santos L; Avigan MI
Drug Saf; 2020 Dec; 43(12):1267-1276. PubMed ID: 32647996
[TBL] [Abstract][Full Text] [Related]
5. What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
Pourcelot AG; Capmas P; Laberge P; Fernandez H
J Gynecol Obstet Hum Reprod; 2020 Apr; 49(4):101688. PubMed ID: 31972353
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity.
Dinis-Oliveira RJ
Drug Metab Rev; 2021 Aug; 53(3):375-383. PubMed ID: 33905271
[TBL] [Abstract][Full Text] [Related]
7. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
8. Acute liver failure requiring transplantation: A possible link to ulipristal acetate treatment?
Dinis-Oliveira RJ; Vieira DN
Basic Clin Pharmacol Toxicol; 2021 Sep; 129(3):278-282. PubMed ID: 34187080
[TBL] [Abstract][Full Text] [Related]
9. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
10. Use of Ulipristal Acetate and Risk of Liver Disease: A Nationwide Cohort Study.
Yoon EL; Yuk JS
J Clin Endocrinol Metab; 2021 May; 106(6):1773-1782. PubMed ID: 33567071
[TBL] [Abstract][Full Text] [Related]
11. Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system.
Gatti M; Fusaroli M; Raschi E; Moretti U; Poluzzi E; De Ponti F
Expert Opin Drug Saf; 2021 Nov; 20(11):1421-1431. PubMed ID: 34280062
[TBL] [Abstract][Full Text] [Related]
12. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!
Rozenberg S; Revercez P; Fastrez M; Vandromme J; Bucella D
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():300-302. PubMed ID: 32650189
[TBL] [Abstract][Full Text] [Related]
13. Fibroid management in premenopausal women.
Donnez J; Courtoy GE; Dolmans MM
Climacteric; 2019 Feb; 22(1):27-33. PubMed ID: 30601065
[TBL] [Abstract][Full Text] [Related]
14. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
16. Ulipristal acetate versus leuprolide acetate for uterine fibroids.
Donnez J; Tomaszewski J; Vázquez F; Bouchard P; Lemieszczuk B; Baró F; Nouri K; Selvaggi L; Sodowski K; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):421-32. PubMed ID: 22296076
[TBL] [Abstract][Full Text] [Related]
17. Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study.
Frijlingh M; De Milliano I; Hehenkamp WJK; Huirne JAF
Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():186-192. PubMed ID: 31679806
[TBL] [Abstract][Full Text] [Related]
18. Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
Ekanem E; Talaulikar V
Adv Ther; 2021 Jan; 38(1):137-148. PubMed ID: 33201387
[TBL] [Abstract][Full Text] [Related]
19. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
20. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
